



SARS-CoV-2 variants vs antibodies

Theodora
Hatzioannou




Using engineered viruses to understand SARS-CoV-2 antibody resistance




Antibody driven variation in cell culture and in natural populations



Plasma selected variants





Naturally occurring variants



PMS20







Omicron




none high

Neutralization assays




Neutralization in convalescent, non-vaccinated individuals


Convalescent 1.3m




Convalescent 6.2m





Convalescent 12m



Neutralization titer (NT₅₀) in vaccinated individuals




Neutralization in convalescent-then vaccinated & vaccinated with 3 doses individuals




Neutralization in convalescent-then vaccinated & vaccinated with 3 doses individuals

Infected then vaccinated (mRNA)



Neutralization in convalescent-then vaccinated & vaccinated with 3 doses individuals




Laboratory of Retrovirology



Paul Bieniasz




Yiska
Weisblum



Frauke
Muecksch

Daniel Poston,
Fengwen Zang

Justin DaSilva Magdalena Rutkowska Fabian Schmidt Eva Bendraski



SCIENCE FOR THE BENEFIT OF HUMANITY

Laboratory of Molecular Immunology

Michel Nussenzweig

Marina Caskey, Christian Gaebler,
Zijun Wang, Alice Cho, Dennis J.
Schaefer-Babajew, Anna Gazumyan,
Shlomo Finkin, Thomas Hägglöf,
Thiago Oliveira, Charlotte Viant,
Marianna Agudelo, Davide Robbiani,
Julio C.C. Lorenzi

Caltech

Pamela Bjorkman
Christopher Barnes

Laboratory of Infectious Diseases

Charlie Rice

Hans Heinrich Hoffman
Eleftheris Michailidis



hhmi
Howard Hughes
Medical Institute